Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2 Jan 18, 2023
Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration Dec 12, 2022
Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments Nov 10, 2022
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202 Oct 27, 2022
Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting Oct 19, 2022
Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting Oct 12, 2022
Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis Oct 5, 2022
Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments Aug 11, 2022
